Nuvation Bio: Rollout Data Of Ibtrozi Support A Modest Buy [Seeking Alpha]
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: Seeking Alpha
IBTROZI's patient starts stabilized at 3.3/day in late 2025, with revenue projections reaching ~$1B by 2030 based upon conservative assumptions. NUVB holds ~$620M in cash, sufficient to reach profitability, minimizing near-term dilution risk as rollout continues. The pipeline, led by safusidenib in Phase III, adds tangible value beyond IBTROZI and further supports a modest bullish case for its stock at $5. spawns/E+ via Getty Images Introduction Nuvation Bio ( NUVB ) is an early commercial-stage biotech company, led by prominent research scientist Dr. David Hung. Its lead asset, IBTROZI, a targeted therapy for ROS1-positive non-small cell lung cancer (NSCLC), was approved by the FDA on June 11, 2025. This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of NUVB either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it
Show less
Read more
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Assessing Nuvation Bio (NUVB) Valuation After Bullish Analyst Calls On Ibtrozi And mIDH1 Glioma Potential [Yahoo! Finance]Yahoo! Finance
- Truist Highlights Nuvation Bio's (NUVB) Ibtrozi's Robust Market Uptake and Lead Over Competitors [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio (NYSE:NUVB) was given a new $13.00 price target on by analysts at Truist Financial Corporation.MarketBeat
- Nuvation Bio (NYSE:NUVB) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- Here's What the Wall Street Thinks About Nuvation Bio Inc. (NUVB) [Yahoo! Finance]Yahoo! Finance
NUVB
Earnings
- 11/3/25 - Beat
NUVB
Sec Filings
- 1/12/26 - Form 8-K
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- NUVB's page on the SEC website